MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma

Clinical Cancer Research

Volumn 13, Issue 14, 2007, Pages 4123-4129

  Hirata, Hiroshi ^a   Hinoda, Yuji ^b   Kikuno, Nobuyuki ^a   Kawamoto, Ken ^a   Suehiro, Yutaka ^b   Tanaka, Yuichiro ^a   Dahiya, Rajvir ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P21; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE;

AGED; CARCINOMA, RENAL CELL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MDM2; RISK FACTORS; SURVIVAL ANALYSIS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34547220487     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0609     Document Type: Article

References (34)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000;50:7-33.
2. Kim WY, Kaelin WG. Role of VHL genemutation in human cancer. J Clin Oncol 2004;22:4991-5004.
3. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7:85-90.
4. Pischon T, Lahmann PH, Boeing H , et al. Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 2006;118:728-38.
5. Semenza JC, Ziogas A, Largent J, Peel D, Anton-Culver H. Gene-environment interactions in renal cell carcinoma. Am J Epidemiol 2001;153:851-9.
6. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
7. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993;366:701-4.
8. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387:296-9.
9. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997;387:299-303.
10. Bond GL, Hu W, Levine A. A single nucleotide polymorphism in the MDM2 gene from a molecular and cellular explanation to clinical effect. Cancer Res 2005;65:5481-4.
11. Boersma BJ, Howe TM, Goodman JE, et al. Association of breast cancer outcome with status of p53 and MDM2 SNP309. J Natl Cancer Inst 2006;98:911-9.
12. Santos AM, Sousa H, Pinto D, et al. Linking TP53 codon 72 and P21 nt590 genotypes to the development of cervical and ovarian cancer. Eur J Cancer 2006;42:958-63.
13. Schabath MB, Wu X, Wei Q, Li G, Gu J, Spitz MR. Combined effects of the p53 and p73 polymorphisms on lung cancer risk. Cancer Epidemiol Biomarkers Prev 2006;15:158-61.
14. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wildtype p53 differ biochemically and biologically. Mol Cell Biol 1999;19:1092-100.
15. Kibel AS, Suarez BK, Belani J, et al. CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. Cancer Res 2003;63:2033-6.
16. Li G, Liu Z, Sturgis EM, et al. Genetic polymorphisms of p21 are associated with risk of squamous cell carcinoma of the head and neck. Carcinogenesis 2005;26:1596-602.
17. Su L, Sai Y, Fan R, et al. P53 (codon 72) and P21 (codon 31) polymorphisms alter in vivo mRNA expression of p21. Lung Cancer 2003;40:259-66.
18. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004;119:591-602.
19. Lind H, Zienolddiny S, Ekstrom PO, Skauq V, Haugen A. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int JCancer 2006;119:718-21.
20. Hong Y, Miao X, Zhang X, et al. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 2005;65:9582-7.
21. Ohmiya N, Taguchi A, Mabuchi N, et al. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol 2006;20:4434-40.
22. Haitel A, Wiener HG, Baethge U, Marberger M, Susani M. mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters. Clin Cancer Res 2000;6:1840-4.
23. Uchida T, Gao JP, Wang C, etal. Clinical significance of p53, mdm2, and bcl-2 proteins in renal cell carcinoma. Urology 2002;59:615-20.
24. Weiss RH, Borowsky AD, Seligson D, et al. p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches. J Urol 2007;177:63-8.
25. Menin C, Scaini MC, De Salvo GL, et al. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst 2006;98:285-8.
26. Keshava C, Frye BL, Wolff MS, McCanlies EC, Weston A. Waf-1 (p21) and p53 polymorphisms in breast cancer. Cancer Epidemiol Biomarkers Prev 2002;11:127-30.
27. Xi YG, Ding KY, Su XL, et al. p53 polymorphism and p21WAF1/CIP1 haplotype in the intestinal gastric cancer and the precancerous lesions. Carcinogenesis 2004;25:2201-6.
28. Ara S, Lee PS, Hansen MF, Saya H. Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res 1990;18:4961.
29. Sotamaa K, Liyanarachchi S, Mecklin JP, et al. p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome. Clin Cancer Res 2005;11:6840-4.
30. Onel K, Cordon-Cardo C. MDM2 and prognosis. Mol Cancer Res 2004;2:1-8.
31. Parker SB, Eichele G, Zhang P , et al. p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells. Science 1995;267:1024-7.
32. Papandreou CN, Bogenrieder T, Loganzo F, Albino AP, Nanus D. Expression and sequence analysis of the p21 (WAF1/CIP1) gene in renal cancers. Urology 1997;49:481-6.
33. Freedman DA, Levine AJ. Regulation of the p53 protein by the MDM2 oncoprotein - thirty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res 1999;59:1-7.
34. Malkin D, Li FP, Strong LC. Germline p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science1990;250:1233-8.